Press Releases Trump Administration’s Interference with the FDA’s Coronavirus Vaccine Guidance Will Cost American Lives October 6, 2020
Letters, Testimony & Filings Comments on the FDA’s Proposal to Exclude 19 Bulk Drug Substances From the 503B Bulks List for Pharmacy Compounding by Outsourced Facilities September 29, 2020
Testimony Before the FDA’s Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee Regarding Reformulated Oxycontin September 11, 2020